Phase 2 results show a statistically significant dose-dependent response on total sleep time with clinically meaningful improvements across multiple sleep measures in children with insomnia disorder, with especially pronounced efficacy… Read More
Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML RAHWAY, N.J., & FOSTER CITY, Calif. Merck… Read More
Provides scalable, decentralized, rapid response testing solutions to enable global expansion. Accelerates expansion into the chronic disease diagnostics market—a large, high-growth, global opportunity—by enabling additional assay development for long-term clinical indications. Creates synergies for sustained breakthrough innovation by combining Sugentech’s cutting edge technology with Response’s rapid response and commercialization capabilities, to support a pipeline of… Read More
Variational AI is pleased to share that Enamine has joined the Agora Open Science Trust collaboration focused on discovering novel PRMT6 inhibitors for Spinal and Bulbar Muscular Atrophy (SBMA), a rare neuromuscular disorder with… Read More
In a world-first study, Terry Fox-funded researchers at Sunnybrook Research Institute are using a specialized ultrasound technique, together with machine learning, to predict tumour response early on in chemotherapy treatment;… Read More
